Even though HLA displayed robust cytotoxicity against tumor cells, our in vitro experiments using expanded splenic T cells showed that treatment of HLA or the conditioned media from HLA-treated EO771 tumor cells selectively enriched CD8+ T cells, which reiterates HLA’s in vivo activity and suggests both the HLA protein itself and the HLA-mediated tumor lysis could increase CD8+ T cells to sensitize the tumors to immunotherapy. This evidence concerns the gene CD8A and neoplasm.